BARD1 Life Sciences Limited (ASX: BD1)
It is estimated that by 2030, 21.6 million people will develop some form of cancer.
While scientists across the world are trying to find a cure, the best way to combat cancer is through early detection.
However, existing blood tests can be unreliable and expensive.
One ASX listed company is building a portfolio of cancer diagnostics for the screening, diagnosis and monitoring of cancer, based on identifying protein biomarkers in the blood.
This company is looking to create a paradigm shift in the early detection market by delivering cheap, less invasive diagnostic tests that could be responsible for saving thousands, if not millions of lives in what amounts to multiple, multi-billion markets.
This ASX Life Sciences company has three main areas of focus with a combined market size of over $30 billion.
The company’s lead product is a lung cancer test, but it is also developing a test for ovarian cancer. These markets alone are worth $33 billion. Add to that a research stage cancer vaccine project in a $7 billion market and there is a lot of upside to this $28.4 million capped company.
The information on this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.
The company is seeking out major diagnostics, government and Big Pharma partners as it looks to bring its products to commercialisation stage in diagnostic markets across the USA, Europe and Australia.
If it can commercialise in these regions, then the company could have a major impact on the lives of cancer sufferers everywhere.